Zeitschrift für Phytotherapie 2015; 36(02): 85-91
DOI: 10.1055/s-0041-100505
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Griffonia simplicifolia

Die wichtigste Quelle für 5-Hydroxytryptophan
M D Josep Lluís Berdonces
Further Information

Publication History

Publication Date:
11 May 2015 (online)


5-Hydroxytryptophan ist eine natürlich ­vorkommende Aminosäure, die in nennenswerter Konzentration in den Samen von Griffonia simplicifolia vorhanden ist und bei der Behandlung der zahlreichen Auswirkungen des Serotoninmangelsyndroms eingesetzt wird. Bereits in den 70er-Jahren wurden Studien zur Wirkung von 5-HTP durchgeführt, entsprechende Arzneimittel mussten aber in Deutschland 1992 vom Markt genommen werden. Präparate aus Griffonia sind seit Mitte der 90er-Jahre als Nahrungsergänzungsmittel verfügbar. Als Anwendungsgebiete gelten u.a. Depressionen, Angststörungen und Adipositas. Die Studienlage ist qualitativ nicht ausreichend.


Griffonia simplicifolia: The most important source for 5-Hydroxytryptophan

5-HTP (5-Hydroxytryptophan) is a naturally-occurring amino acid that is found in ­significant concentrations in the seeds of Griffonia simplicifolia. It is used in the treatment of numerous effects of serotonin deficiency syndrome. As early as the 1970s, studies on the effect of 5-HTP had already been undertaken. However, in 1992 ­respective 5-HTP remedies had to be taken away from the German market. Since the mid 1990s, Griffonia preparations are available as dietary supplements. The areas of application include: depression, anxiety disorders and adiposity. Nonetheless, most studies on these remedies are not of sufficient quality.

  • Literatur

  • 1 Addotey J. Local production of 5-HTP from the seeds of Griffonia simplicifolia [Master-Thesis]. 2009 http://ir.knust.edu.gh/handle/123456789/92
  • 2 Bruni O, Ferri R, Miano S, Verrillo E. L-5-Hydroxytryptophan treatment of sleep terrors in children. Eur J Pediatr 2004; 163: 402-407
  • 3 Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987; 7: 127-137
  • 4 Cangiano C, Ceci F, Cascino A et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992; 56: 863-867
  • 5 Carnevale G, Di Viestia V, Zavatti M et al. Influence of Griffonia simplicifolia on male sexual behavior in rats: behavioral and neurochemical study. Phytomedicine 2011; 18: 947-952
  • 6 Carnevale G, Di Viestia V, Zavatti M et al. Griffonia simplicifolia negatively affects sexual behavior in female rats. Phytomedicine 2010; 17: 987-991
  • 7 Carnevale G, Di Viestia V, Zavatti M, Zanoli P. Anxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats. Phytomedicine 2011; 18: 848-851
  • 8 Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990; 18: 201-209
  • 9 Coleman M. Infantile spasms associated with 5-hydroxytryptophan administration in patients with Down’s syndrome. Neurology 1971; 21: 911-919
  • 10 Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicol Lett 2004; 150: 111-122
  • 11 Emanuele E, Bertona M, Minoretti P et al. An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress. Neuro Endocrinol Lett 2010; 31: 663-666
  • 12 Freedman RR. Treatment of menopausal hot flashes with 5-hydroxytryptophan. Maturitas 2010; 65: 383-385
  • 13 Gambichler T, Bader A, Vojvodic M et al. Impact of UVA exposure on psychological parameters and circulating serotonin and melatonin. BMC Dermatol 2002; 2-6
  • 14 Hinz M, Stein A, Uncini T. 5-HTP efficacy and contraindications. Neuropsychiatr Dis Treat 2012; 8: 323-328
  • 15 Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002; 112: 135-140
  • 16 Jangid P, Malik P, Singh P et al. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Toxicol Lett 2004; 150: 111-122
  • 17 Johnson KL, Klarskov K, Benson LM et al. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. J Rheumatol 1999; 26: 2714-2717
  • 18 Juhl JH. Fibromyalgia and the serotonin pathway. Altern Med Rev 1998; 3: 367-375
  • 19 Kahn RS, Westenberg HG. L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affect Disord 1985; 8: 197-200
  • 20 Lemaire PA, Adosraku RK. An HPLC method for the direct assay of the serotonin precursor, 5-hydroxytrophan, in seeds of Griffonia simplicifolia . Phytochemical Analysis 2002; 13: 333-337
  • 21 Lin Y, Sun X, Yuan Q, Yan Y. Engineering bacterial phenylalanine 4-hydroxylase for microbial synthesis of human neurotransmitter precursor 5-hydroxytryptophan. ACS Synth Biol 2014; 3: 497-505
  • 22 Maron E, Tõru I, Vasar V, Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-­induced panic attacks in healthy volunteers. J Psychopharmacol 2004; 18: 194-199
  • 23 Michelson D, Page SW, Casey R et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994; 21: 2261-2265
  • 24 Nakajima T, Kudo Y, Kaneko Z. Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug. Folia Psychiatr Neurol Jpn 1978; 32: 223-230
  • 25 Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol 1996; 398: 373-379
  • 26 Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5 HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. Br J Psychiatry 1985; 147: 16-22
  • 27 Ribeiro CA. L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. Headache 2000; 40: 451-456
  • 28 Robinson N, Curzon G, Theaker P. Excretion of tryptophan metabolites in Friedreich’s ataxia. J Clin Pathol 1965; 18: 797-799
  • 29 Rondanelli M, Klersy C, Iadarola P et al. Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation. Int J Obes (Lond) 2009; 33: 1174-1182
  • 30 Rondanelli M, Opizzi A, Faliva M et al. Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eat Weight Disord 2012; 17: e22-28
  • 31 Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992; 20: 182-189
  • 32 Schruers K, van Diest R, Overbeek T, Griez E. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res 2002; 113: 237-243
  • 33 Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002. (1) CD003198
  • 34 Smarius LJ, Jacobs GE et al. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. J Psychopharmacol 2008; 22: 426-433
  • 35 Sternberg EM, Van Woert MH, Young SN et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 1980; 303: 782-787
  • 36 Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan: a double-blind study with quantified data processing. Arch Neurol 1988; 45: 1217-1222
  • 37 Trujillo-Martín MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord 2009; 24: 1111-1124
  • 38 Turner EH, Blackwell AD. 5-Hydroxytryptophan plus SSRIs for interferon-induced depression. Med Hypotheses 2005; 65: 138-144
  • 39 Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 2006; 109: 325-338
  • 40 van Praag H, de Hann S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 1980; 3: 75-83
  • 41 van Praag H, de Hann S. Chemoprophylaxis of depressions. An attempt to compare lithium with 5-hydroxytryptophan. Acta Psychiatr Scand Suppl 1981; 290: 191-201
  • 42 Wang XZ, Wu FH, Qu W, Liang JY. A new β-carboline alkaloid from the seeds of Griffonia simplicifolia . Chin J Nat Med 2013; 11: 401-405
  • 43 Weise P, Koch R, Shaw KN et al. The use of 5-HTP in the treatment of Down’s syndrome. Pediatrics 1974; 54: 165-168
  • 44 Zmilacher K, Battegay R, Gastpar M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988; 20: 28-35